How to generate reliable and predictive CoMFA models.

Comparative Molecular Field Analysis (CoMFA) is a mainstream and down-to-earth 3D QSAR technique in the coverage of drug discovery and development. Even though CoMFA is remarkable for high predictive capacity, the intrinsic data-dependent characteristic still makes this methodology certainly be handicapped by noise. It's well known that the default settings in CoMFA can bring about predictive QSAR models, in the meanwhile optimized parameters was proven to provide more predictive results. Accordingly, so far numerous endeavors have been accomplished to ameliorate the CoMFA model's robustness and predictive accuracy by considering various factors, including molecular conformation and alignment, field descriptors and grid spacing. Herein, we would like to make a comprehensive survey of the conceivable descriptors and their contribution to the CoMFA model's predictive ability.

[1]  Minyong Li,et al.  A comparison of different electrostatic potentials on prediction accuracy in CoMFA and CoMSIA studies. , 2010, European journal of medicinal chemistry.

[2]  R. Giridhar,et al.  Understanding the antitumor activity of novel tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA. , 2006, European journal of medicinal chemistry.

[3]  Hai-Feng Chen,et al.  Computational study of histamine H3-receptor antagonist with support vector machines and three dimension quantitative structure activity relationship methods. , 2008, Analytica chimica acta.

[4]  Dhilon S. Patel,et al.  3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3beta inhibitors. , 2007, Journal of molecular graphics & modelling.

[5]  I. Pajeva,et al.  Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study. , 1998, Journal of medicinal chemistry.

[6]  H. Kubinyi.  QSAR : Hansch analysis and related approaches , 1993 .

[7]  Asit K Chakraborti,et al.  3D-QSAR studies of indole derivatives as phosphodiesterase IV inhibitors. , 2003, European journal of medicinal chemistry.

[8]  Peter Gedeck,et al.  Use of the R-group descriptor for alignment-free QSAR , 2005 .

[9]  Tanaji T. Talele,et al.  Structure-based CoMFA and CoMSIA study of indolinone inhibitors of PDK1 , 2009, J. Comput. Aided Mol. Des..

[10]  L. Meijer,et al.  Evaluation and comparison of 3D-QSAR CoMSIA models for CDK1, CDK5, and GSK-3 inhibition by paullones. , 2004, Journal of medicinal chemistry.

[11]  K Tuppurainen,et al.  Frontier orbital energies, hydrophobicity and steric factors as physical QSAR descriptors of molecular mutagenicity. A review with a case study: MX compounds. , 1999, Chemosphere.

[12]  S. Wold,et al.  Comparative molecular field analysis , 1991 .

[13]  R. Bursi,et al.  Structure–activity relationship study of human liver microsomes-catalyzed hydrolysis rate of ester prodrugs of MENT by comparative molecular field analysis (CoMFA) , 2003, Steroids.

[14]  Karl Pearson F.R.S..  LIII. On lines and planes of closest fit to systems of points in space , 1901 .

[15]  Bruce L. Bush,et al.  Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA , 1993, J. Comput. Aided Mol. Des..

[16]  H. Kubinyi.  QSAR and 3D QSAR in drug design Part 1: methodology , 1997 .

[17]  Jianfeng Pei,et al.  3D-QSAR and Receptor Modeling of Tyrosine Kinase Inhibitors with Flexible Atom Receptor Model (FLARM) , 2003, J. Chem. Inf. Comput. Sci..

[18]  Pramod C. Nair,et al.  CoMFA based de novo design of pyridazine analogs as PTP1B inhibitors. , 2007, Journal of molecular graphics & modelling.

[19]  Huanxiang Liu,et al.  Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking. , 2009, Journal of molecular graphics & modelling.

[20]  David E Reichert,et al.  Use of binding energy in comparative molecular field analysis of isoform selective estrogen receptor ligands. , 2004, Journal of molecular graphics & modelling.

[21]  O. Vajragupta,et al.  Comparative quantitative structure-activity study of radical scavengers. , 2000, Bioorganic & medicinal chemistry.

[22]  Thy-Hou Lin,et al.  A Ligand-Based Molecular Modeling Study on Some Matrix Metalloproteinase-1 Inhibitors Using Several 3D QSAR Techniques , 2004, J. Chem. Inf. Model..

[23]  Wesley Schaal,et al.  Improved CoMFA Modeling by Optimization of Settings , 2006, J. Chem. Inf. Model..

[24]  Molecular Docking and 3‐D QSAR Studies of Substituted 2,2‐Bisaryl‐Bicycloheptanes as Human 5‐Lipoxygenase‐Activating Protein (FLAP) Inhibitors , 2008 .

[25]  Y. Martin,et al.  Direct prediction of dissociation constants (pKa's) of clonidine-like imidazolines, 2-substituted imidazoles, and 1-methyl-2-substituted-imidazoles from 3D structures using a comparative molecular field analysis (CoMFA) approach. , 1991, Journal of medicinal chemistry.

[26]  H. Kubinyi.  QSAR and 3D QSAR in drug design Part 2: applications and problems , 1997 .

[27]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[28]  J Pei,et al.  PARM: a practical utility for drug design. , 2001, Journal of molecular graphics & modelling.

[29]  Ding-Yah Yang,et al.  3D-QSAR studies on 4-hydroxyphenylpyruvate dioxygenase inhibitors by comparative molecular field analysis (CoMFA). , 2002, Bioorganic & medicinal chemistry letters.

[30]  Lowell H. Hall,et al.  E-State Modeling of Corticosteroids Binding AffinityValidation of Model for Small Data Set , 2001, J. Chem. Inf. Comput. Sci..

[31]  R. Cramer,et al.  Topomer CoMFA: a design methodology for rapid lead optimization. , 2003, Journal of medicinal chemistry.

[32]  Han van de Waterbeemd,et al.  Chemometric methods in molecular design , 1995 .

[33]  Michael R. Greenberg,et al.  Chapter 1 – Theory, Methods, and Applications , 1978 .

[34]  G Klebe,et al.  On the prediction of binding properties of drug molecules by comparative molecular field analysis. , 1993, Journal of medicinal chemistry.

[35]  Quantitative Structure‐Retention Relationship of Nucleic‐Acid Bases Revisited. CoMFA on Purine RPLC Retention , 2005 .

[36]  W. Sippl,et al.  Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors. , 2009, European journal of medicinal chemistry.

[37]  P. Bharatam,et al.  3D-QSAR studies of substituted 1-(3, 3-diphenylpropyl)-piperidinyl amides and ureas as CCR5 receptor antagonists , 2007, Journal of molecular modeling.

[38]  Patchreenart Saparpakorn,et al.  Particular interaction between pyrimethamine derivatives and quadruple mutant type dihydrofolate reductase of Plasmodium falciparum: CoMFA and quantum chemical calculations studies. , 2009, Journal of enzyme inhibition and medicinal chemistry.

[39]  P. Bharatam,et al.  3D-QSAR analysis of cycloguanil derivatives as inhibitors of A16V + S108T mutant Plasmodium falciparum dihydrofolate reductase enzyme. , 2009, Journal of molecular graphics & modelling.

[40]  D. Ferguson,et al.  QSAR and CoMFA: a perspective on the practical application to drug discovery. , 2000, Drug Design and Discovery.

[41]  Toshio Fujita,et al.  A Novel Three‐Dimensional QSAR Procedure: Voronoi Field Analysis , 1998 .

[42]  A. Tropsha,et al.  Beware of q2! , 2002, Journal of molecular graphics & modelling.

[43]  R. Zauhar,et al.  Computational studies on HIV-1 protease inhibitors: influence of calculated inhibitor-enzyme binding affinities on the statistical quality of 3D-QSAR CoMFA models. , 2000, Journal of medicinal chemistry.

[44]  R. Mckinnon,et al.  Effect of steric molecular field settings on CoMFA predictivity , 2008, Journal of molecular modeling.

[45]  Lowell H. Hall,et al.  E-State Modeling of Corticosteroids Binding Affinity Validation of Model for Small Data Set. , 2001 .

[46]  Markus A Lill,et al.  Multi-dimensional QSAR in drug discovery. , 2007, Drug discovery today.

[47]  Alexander Tropsha,et al.  The effect of region size on CoMFA analyses , 1999 .

[48]  Shuyan Li,et al.  Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of thiazolone derivatives as hepatitis C virus NS5B polymerase allosteric inhibitors , 2008, J. Comput. Aided Mol. Des..

[49]  Euzébio G. Barbosa,et al.  LQTA-QSAR: A New 4D-QSAR Methodology , 2009, J. Chem. Inf. Model..

[50]  W. Schmidt,et al.  Steric and electrostatic effects in dye-cellulose interactions by the MTD and CoMFA approaches , 2002, SAR and QSAR in environmental research.

[51]  Guang-Fu Yang,et al.  Development of quantitative structure-activity relationships and its application in rational drug design. , 2006, Current pharmaceutical design.

[52]  Yong-Jun Jiang,et al.  3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. , 2009, European journal of medicinal chemistry.

[53]  Balázs Jójárt,et al.  Receptor-based QSAR studies of non-peptide human oxytocin receptor antagonists. , 2007, Journal of molecular graphics & modelling.

[54]  A Palomer,et al.  Derivation of pharmacophore and CoMFA models for leukotriene D(4) receptor antagonists of the quinolinyl(bridged)aryl series. , 2000, Journal of medicinal chemistry.

[55]  Robert E. Hormann,et al.  An extensive ecdysteroid CoMFA , 1999, J. Comput. Aided Mol. Des..

[56]  Z. Xi,et al.  Study on structure-activity relationship of mutation-dependent herbicide resistance acetohydroxyacid synthase through 3D-QSAR and mutation , 2007 .

[57]  Tommi H. Nyrönen,et al.  Comparing the Quality and Predictiveness between 3D QSAR Models Obtained from Manual and Automated Alignment , 2004, J. Chem. Inf. Model..

[58]  G. Zeng,et al.  3D-QSAR study of sulfonamide inhibitors of human carbonic anhydrase II. , 2007, European journal of medicinal chemistry.

[59]  Klaus R. Liedl,et al.  Improving the Predictive Quality of CoMFA Models , 1998 .

[60]  H. Kubinyi,et al.  3D QSAR in drug design. , 2002 .

[61]  Michel Petitjean,et al.  Insight into the Bioactivity and Metabolism of Human Glucagon Receptor Antagonists from 3D‐QSAR Analyses , 2004 .

[62]  Jiaju Zhou,et al.  Pseudoreceptor Models and 3D-QSAR for Imidazobenzodiazepines at GABAA/BzR Subtypes alphaxbeta3gamma2 [x = 1-3, 5, and 6] via Flexible Atom Receptor Model , 2004, J. Chem. Inf. Model..

[63]  William J. Welsh,et al.  Three-Dimensional Quantitative Structure-Property Relationship (3D-QSPR) Models for Prediction of Thermodynamic Properties of Polychlorinated Biphenyls (PCBs): Enthalpy of Vaporization , 2002, J. Chem. Inf. Comput. Sci..

[64]  N. Tawari,et al.  3‐D‐QSAR Analysis of 2‐(Oxalylamino) benzoic acid Class of Protein Tyrosine Phosphatase 1B Inhibitors by CoMFA and Cerius2.GA , 2007 .

[65]  H Hanhijärvi,et al.  Comparative molecular field analysis of some clodronic acid esters. , 1991, Journal of medicinal chemistry.

[66]  M. Degani,et al.  Pharmacophore Refinement and 3D-QSAR Studies of Histamine H3 Antagonists , 2007 .

[67]  R. Bursi,et al.  A three-dimensional quantitative structure-activity relationship study of heparin-binding epidermal growth factor shedding inhibitors using comparative molecular field analysis. , 2002, Journal of medicinal chemistry.

[68]  Lisa Harris,et al.  Partial Charge Calculation Method Affects CoMFA QSAR Prediction Accuracy , 2009, J. Chem. Inf. Model..

[69]  Peter D. J. Grootenhuis,et al.  Comparative molecular field analysis and energy interaction studies of thrombin-inhibitor complexes , 1999, J. Comput. Aided Mol. Des..

[70]  William J. Welsh,et al.  Three-Dimensional Quantitative Structure-Property Relationship (3D-QSPR) Models for Prediction of Thermodynamic Properties of Polychlorinated Biphenyls (PCBs): Enthalpy of Sublimation , 2002, J. Chem. Inf. Comput. Sci..

[71]  Yang Xu,et al.  3D‐QSAR Studies on a Class of IKK‐2 Inhibitors with GALAHAD Used to Develop Molecular Alignment Models , 2008 .

[72]  Alexander Golbraikh,et al.  Rational selection of training and test sets for the development of validated QSAR models , 2003, J. Comput. Aided Mol. Des..

[73]  Minghua Qiu,et al.  3D-QSAR and docking studies of aminopyridine carboxamide inhibitors of c-Jun N-terminal kinase-1. , 2008, European journal of medicinal chemistry.

[74]  S. Sinning,et al.  QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter. , 2007, Bioorganic & medicinal chemistry.

[75]  H. Kubinyi.  Comparative Molecular Field Analysis (CoMFA) , 2002 .

[76]  Yoshiaki Nakagawa,et al.  Classical and three-dimensional QSAR for the inhibition of [3H]ponasterone A binding by diacylhydrazine-type ecdysone agonists to insect Sf-9 cells. , 2005, Bioorganic & medicinal chemistry.

[77]  Robert D. Clark,et al.  Boosted leave-many-out cross-validation: the effect of training and test set diversity on PLS statistics , 2003, J. Comput. Aided Mol. Des..

[78]  David A. Demeter,et al.  The Local Minima Method (LMM) of Pharmacophore Determination: A Protocol for Predicting the Bioactive Conformation of Small, Conformationally Flexible Molecules , 1998, J. Chem. Inf. Comput. Sci..

[79]  Jonathan D. Hirst,et al.  On the Stability of CoMFA Models , 2004, J. Chem. Inf. Model..

[80]  Hao Chen,et al.  Improving the Quality of 3D-QSAR by Using Flexible-Ligand Receptor Models , 2005, J. Chem. Inf. Model..

[81]  M. Jung,et al.  CoMFA of artemisinin derivatives: effect of location and size of lattice. , 2001, Bioorganic & medicinal chemistry letters.

[82]  E. Coutinho,et al.  A CoMFA study of COX-2 inhibitors with receptor based alignment. , 2004, Journal of molecular graphics & modelling.

[83]  Deborah A. Loughney,et al.  A comparison of progestin and androgen receptor binding using the CoMFA technique , 1992, J. Comput. Aided Mol. Des..

[84]  J. Sufrin,et al.  Steric mapping of the L-methionine binding site of ATP:L-methionine S-adenosyltransferase. , 1981, Molecular pharmacology.

[85]  A. Hopfinger,et al.  Construction of 3D-QSAR Models Using the 4D-QSAR Analysis Formalism , 1997 .

[86]  I. Park,et al.  Molecular modeling of 3-arylisoquinoline antitumor agents active against A-549. A comparative molecular field analysis study. , 2002, Bioorganic & medicinal chemistry.

[87]  Jaroslaw Polanski,et al.  Probability issues in molecular design: predictive and modeling ability in 3D-QSAR schemes. , 2004, Combinatorial chemistry & high throughput screening.

[88]  Han Van De Waterbeemd.  Advanced Computer-Assisted Techniques in Drug Discover , 1994 .